Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: A population-based study

Archives of Internal Medicine

Volumn 170, Issue 12, 2010, Pages 1045-1049

  Antoniou, Tony ^a,c   Gomes, Tara ^a,e   Juurlink, David N ^a,b,e,f   Loutfy, Mona R ^a,b,g   Glazier, Richard H ^a,b,c,e   Mamdani, Muhammad M ^a,d,e,h  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^f SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^g WOMEN S COLLEGE HOSPITAL   (Canada)

^h KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CIPROFLOXACIN; COTRIMOXAZOLE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITROFURANTOIN; NORFLOXACIN;

AGED; ANTIBIOTIC THERAPY; ARTICLE; CANADA; CONTROLLED STUDY; ELDERLY CARE; FEMALE; HOSPITALIZATION; HUMAN; HYPERKALEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERKALEMIA; INCIDENCE; MALE; ONTARIO; POPULATION SURVEILLANCE; POTASSIUM; PROGNOSIS; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES; RISK FACTORS; SULFAMETHIZOLE; TIME FACTORS; TRIMETHOPRIM; URINARY TRACT INFECTIONS;

EID: 77954192913     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2010.142     Document Type: Article

References (23)

1. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G; The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensinconverting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145-153.
2. Yusuf S, Teo KK, Pogue J, et al; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358 (15):1547-1559.
3. Agodoa LY, Appel L, Bakris GL, et al; African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285(21):2719-2728.
4. Thomas GN, Tomlinson B. Prevention of macrovascular disease in type 2 diabetic patients: blockade of the renin-angiotensin-aldosterone system. Curr Diabetes Rev. 2008;4(1):63-78.
5. Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors: how much should we worry? Arch Intern Med. 1998;158(1):26-32.
6. Ahuja TS, Freeman D Jr, Mahnken JD, Agraharkar M, Siddiqui M, Memon A. Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors. Am J Nephrol. 2000;20(4):268-272.
7. Palmer BF. Managing hyperkalemia caused by inhibitors of the rennin-angiotensin-aldosterone system. N Engl J Med. 2004;351(6):585-592.
8. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003;289 (13):1652-1658.
9. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351 (6):543-551.
10. Ponce SP, Jennings AE, Madias NE, Harrington JT. Drug-induced hyperkalemia. Medicine (Baltimore). 1985;64(6):357-370.
11. Eiam-Ong S, Kurtzman NA, Sabatini S. Studies on the mechanism of trimethoprim-induced hyperkalemia. Kidney Int. 1996;49(5):1372-1378.
12. Velázquez H, Perazella MA, Wright FS, Ellison DH. Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med. 1993;119(4):296-301.
13. Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med. 2006;354(13):1352-1361.
14. Lipscombe LL, Gomes T, Lévesque LE, Hux JE, Juurlink DN, Alter DA. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA. 2007;298(22):2634-2643.
15. Lubin JH, Gail MH. Biased selection of controls for case-control analyses of cohort studies. Biometrics. 1984;40(1):63-75.
16. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care. 2002;25(3):512-516.
17. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med. 2007;26(4):734-753.
18. Appel GB, Garvey G, Silva F, Francke E, Neu HC, Weissman J. Acute interstitial nephritis due to amoxicillin therapy. Nephron. 1981;27(6):313-315. (Pubitemid 11072578)
19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
20. Bugge JF. Severe hyperkalemia induced by trimethoprim in combination with an angiotensin-converting enzyme inhibitor in a patient with transplanted lungs. J Intern Med. 1996;240(4):249-251.
21. Alappan R, Buller GK, Perazella MA. Trimethoprim-sulfamethoxazole therapy in outpatients: is hyperkalemia a significant problem? Am J Nephrol. 1999;19 (3):389-394.
22. Marinella MA. Trimethoprim-induced hyperkalemia: an analysis of reported cases. Gerontology. 1999;45(4):209-212.
23. Canaday DH, Johnson JR. Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole. Ann Intern Med. 1994;120(5):437-438.